% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • oceanharaso oceanharaso Jun 5, 2013 5:17 PM Flag

    As a physician scientist following this story peripherally for some time

    a look at these data gives me a lot of confidence in the phase III study. First, in GALAXY-1 the OS for all adenoca pts with Cox regression has p 0.04 with 90% CI .55 to .98. That is excellent for a phase II study that was not powered, as should be the case, to achieve statistical signicance. Secondly I think the data are poorly presented visually since the OS is the key parameter - they should at least have a bold vertical line on the Kaplan Meier curves showing the quite large differences. They do need some lessons in how to promote their data. Frankly, the thing that concerns me most is the selection of a subgroup with better prognosis for phase III, even though that makes some sense based on the available data. Wish they wouid have stuck to their guns. Hey, overexpression of Hsp90 is linked to poor prognosis. Based on the science, the poor prognosis patients are their ideal target population. Plus the failure to rely on primary outcome measures always raises suspicion, and in this case, resulted in a unreasonable negative response to the data. I made a big initial investment today and will buy more if the opportunity arises. I should mention that I'm nearly always right - I would have made a fortune in the market if I didn't find this stuff so boring.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.343+0.072(+26.61%)Jul 22 4:00 PMEDT